<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03887208</url>
  </required_header>
  <id_info>
    <org_study_id>2ABC Therapy</org_study_id>
    <secondary_id>2016-004110-10</secondary_id>
    <secondary_id>267976/13/NCBR/2015</secondary_id>
    <secondary_id>PL008125</secondary_id>
    <secondary_id>Z4217</secondary_id>
    <nct_id>NCT03887208</nct_id>
  </id_info>
  <brief_title>Therapy of Scars and Cutis Laxa With Autologous Adipose Derived Mesenchymal Stem Cells</brief_title>
  <acronym>2ABC</acronym>
  <official_title>Evaluation the Safety and Efficacy of the Treatment of Scars and Cutis Laxa Syndrome With the Use of Autologous (Fresh and Stored) Stem Cells Isolated From Adipose Tissue.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Timeless Chirurgia Plastyczna-Janusz Jaworowski</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Melitus sp. z o.o.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Polish Stem Cells Bank S.A.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Warsaw</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare clinical outcomes of patients with large scars or Cutis&#xD;
      laxa treated with injections of autologous stromal vascular fraction cells (SVF) and&#xD;
      adipose-derived mesenchymal stem cells (ADSC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients suffering from cutis laxa senilis and scars (atrophic, hypertrophic, developed due&#xD;
      to surgery, trauma, diseases such as acne vulgaris, post-burn scars) will be treated with&#xD;
      product containing - human autologous stromal vascular fraction (SVF) cells and human&#xD;
      autologous adipose-derived mesenchymal stem cells (ADSC)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 31, 2018</start_date>
  <completion_date type="Actual">January 31, 2019</completion_date>
  <primary_completion_date type="Actual">January 31, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients receive injections of autologous SVF or ADSC cells isolated in the laboratory from adipose tissue.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in patient's skin condition</measure>
    <time_frame>0-27 weeks</time_frame>
    <description>Evaluation of the effectiveness of the method of application of stem cells in the described indications by evaluating the time after which there will be an improvement of 50% in the point evaluation scale of the quality of life of the patient in relation to the baseline values.&#xD;
Scale 1: Impact of skin problems on the quality of life. The aim is to assess to what extent skin ailments have affected the patient's life in the last 2 weeks.&#xD;
A five-level scale of evaluation (from 'very strong' to 'not applicable') .The &quot;very strong&quot; value means the worst result, while the &quot;not applicable&quot; value is the best result.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of skin problems. Assessment of skin related complaints since the last visit.</measure>
    <time_frame>0-27 weeks</time_frame>
    <description>Scale 2: A seven-level grading scale (from &quot;0&quot; to &quot;6&quot;).The value &quot;0&quot; means the best result, while &quot;6&quot; is the worst result.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The assessment of the scar by the patient.</measure>
    <time_frame>0-27 weeks</time_frame>
    <description>Scale 3: Six-point scale (from '1' to '6'). The value &quot;1&quot; means the best result, while &quot;6&quot; is the worst result.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in volume of the skin (USG)</measure>
    <time_frame>0-27 weeks</time_frame>
    <description>Changes in the volume of the fat layer at the application site assessed by skin (USG) thickness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in skin surface morphology (digital imagining)</measure>
    <time_frame>0-27 weeks</time_frame>
    <description>Changes in skin surface morphology assessed by digital imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Record of adverse events</measure>
    <time_frame>0-27 weeks</time_frame>
    <description>Evaluation of safety of the method of cells' application assessed by adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Skin</condition>
  <condition>Scar</condition>
  <condition>Cutis Laxa</condition>
  <condition>Keloid</condition>
  <condition>Cicatrix</condition>
  <arm_group>
    <arm_group_label>Autologous adipose derived stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous ADSC injection combined with laser therapy of the skin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Normal saline injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal sline injection combined with laser therapy of the skin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laser therapy</intervention_name>
    <description>non-ablative fractional laser therapy of skin</description>
    <arm_group_label>Autologous adipose derived stem cells</arm_group_label>
    <arm_group_label>Placebo - Normal saline injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous ADSC injection</intervention_name>
    <description>Subcutaneous injection of autologous ADSC</description>
    <arm_group_label>Autologous adipose derived stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Normal saline injection</intervention_name>
    <description>Subcutaneous Normal saline injection</description>
    <arm_group_label>Placebo - Normal saline injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 - 75 years at the time of qualification to the study&#xD;
&#xD;
          2. Signing informed consent form&#xD;
&#xD;
          3. Women / men&#xD;
&#xD;
          4. Scar or cutis laxa&#xD;
&#xD;
             Scar eligibility conditions:&#xD;
&#xD;
               -  Area:&#xD;
&#xD;
                    -  Stomach&#xD;
&#xD;
                    -  Limbs&#xD;
&#xD;
                    -  Face&#xD;
&#xD;
                    -  Back&#xD;
&#xD;
                    -  Chest and neck&#xD;
&#xD;
                         -  Onset time: over 6 months&#xD;
&#xD;
                         -  Scars previously untreated&#xD;
&#xD;
                         -  Atrophic and hypertrophic scars&#xD;
&#xD;
                         -  Two scars in close location, each from 2 to 6 cm long and a total&#xD;
                            surface area of 1 sq. cm to 5 sq. cm or single scar&#xD;
&#xD;
               -  Etiology&#xD;
&#xD;
                    -  traumatic&#xD;
&#xD;
                    -  burns&#xD;
&#xD;
                    -  surgical&#xD;
&#xD;
             Cutis laxa eligibility conditions:&#xD;
&#xD;
               -  Sun discoloration&#xD;
&#xD;
               -  Pigmentation changes&#xD;
&#xD;
               -  Solar stains&#xD;
&#xD;
               -  Pigment changes also called age spots.&#xD;
&#xD;
               -  Erythema&#xD;
&#xD;
               -  Cracked blood vessels&#xD;
&#xD;
               -  Ruby nevus&#xD;
&#xD;
               -  Atrophic changes of the skin and subcutaneous tissue&#xD;
&#xD;
               -  Changes symmetrically present on both hands&#xD;
&#xD;
          5. Without previous aesthetic treatment in this area, previous standard care.&#xD;
&#xD;
          6. Patient's health which allows anesthesia for liposuction.&#xD;
&#xD;
          7. Ready for follow-up visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active cancer (diagnosed during past 5 years), excluding cured nonmelanoma skin cancer&#xD;
             or other non-invasive or in situ cancer (eg. cervical cancer)&#xD;
&#xD;
          2. Active chronic infection&#xD;
&#xD;
          3. Chronic use of NSAIDs&#xD;
&#xD;
          4. Taking any anticoagulant by the patient during 1 hour prior to surgery (excluding&#xD;
             prophylactic heparin before liposuction).&#xD;
&#xD;
          5. Coagulation disorders in medical history and actual test results out of normal ranges.&#xD;
&#xD;
          6. Skin infections.&#xD;
&#xD;
          7. Allergies to medications used during liposuction (eg. Lidocaine and derivatives).&#xD;
&#xD;
          8. Status post radiotherapy or chemotherapy&#xD;
&#xD;
          9. Any other disease or condition that may change the evaluation of skin condition (eg.&#xD;
             autoimmune disease of the connective tissue)&#xD;
&#xD;
         10. Taking the corticosteroid drugs or cytotoxic medications during the past 30 days&#xD;
&#xD;
         11. Allergy to materials of animal origin&#xD;
&#xD;
         12. Diagnosis of diabetes Type I&#xD;
&#xD;
         13. Diagnosis of AIDS, hepatitis B virus (HBV) or hepatitis C virus (HCV) (positive&#xD;
             laboratory test result)&#xD;
&#xD;
         14. Hirsutism or a tattoo at the treatment site&#xD;
&#xD;
         15. Insufficient fat tissue for fat donation&#xD;
&#xD;
         16. Scar after removal of cancer.&#xD;
&#xD;
         17. The patient does not qualify to participate in this study in the opinion of the&#xD;
             investigator&#xD;
&#xD;
         18. Pregnancy, breast feeding.&#xD;
&#xD;
         19. Photoallergy or using the drugs causing photoallergy.&#xD;
&#xD;
         20. Active herpes&#xD;
&#xD;
         21. Idiopathic keloids&#xD;
&#xD;
         22. Esthetic or medicinal treatments done previously at the treatment site&#xD;
&#xD;
         23. The use of derivatives of vitamin A during 6 months before the treatment&#xD;
&#xD;
         24. Fitzpatrick phototype V and VI&#xD;
&#xD;
         25. Patients with mental disorders or addicted to drugs and/or alcohol.&#xD;
&#xD;
         26. Participation in other clinical study during the past 6 months.&#xD;
&#xD;
         27. Reactive result of serological and viral tests (ie. HIV-1 and 2 (HIV Ag/ Ab)&#xD;
&#xD;
               -  Hepatitis B Virus Infection, - HbsAg and Anti-hepatitis B core antigen&#xD;
                  (Anti-HBc);&#xD;
&#xD;
               -  Hepatitis C Virus Infection, Anti-HCV;&#xD;
&#xD;
               -  Syphilis specific tests&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Noszczyk-Kostrzewa, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Melitus Ltd</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Janusz R Jaworowski, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Timeless Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laboratory for Cell Research and Application, Medical University of Warsaw</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melitus sp. z o.o.</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Timeless Chirurgia Plastyczna Sp. z o. o.</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 30, 2018</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2019</study_first_posted>
  <last_update_submitted>January 27, 2020</last_update_submitted>
  <last_update_submitted_qc>January 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>scar treatment</keyword>
  <keyword>cutis laxa treatment</keyword>
  <keyword>stromal vascular fraction</keyword>
  <keyword>adipose-derived mesenchymal stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cutis Laxa</mesh_term>
    <mesh_term>Cicatrix</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

